• Focus Areas
    • Cause Selection
    • Global Health & Wellbeing
      • Effective Altruism Community Growth (Global Health and Wellbeing)
      • Farm Animal Welfare
      • Global Aid Policy
      • Global Health & Development
      • Scientific Research
      • South Asian Air Quality
    • Longtermism
      • Biosecurity & Pandemic Preparedness
      • Effective Altruism Community Growth (Longtermism)
      • Potential Risks from Advanced AI
    • Other Areas
      • Criminal Justice Reform
      • History of Philanthropy
      • Immigration Policy
      • Land Use Reform
      • Macroeconomic Stabilization Policy
  • Grants
  • Research & Updates
    • Research Reports
    • Blog Posts
    • Notable Lessons
    • In the News
  • About Us
    • Grantmaking Process
    • How to Apply for Funding
    • Team
    • Contact Us
    • Stay Updated
  • We’re hiring!
  • Focus Areas
    • Cause Selection
    • Global Health & Wellbeing
      • Effective Altruism Community Growth (Global Health and Wellbeing)
      • Farm Animal Welfare
      • Global Aid Policy
      • Global Health & Development
      • Scientific Research
      • South Asian Air Quality
    • Longtermism
      • Biosecurity & Pandemic Preparedness
      • Effective Altruism Community Growth (Longtermism)
      • Potential Risks from Advanced AI
    • Other Areas
      • Criminal Justice Reform
      • History of Philanthropy
      • Immigration Policy
      • Land Use Reform
      • Macroeconomic Stabilization Policy
  • Grants
  • Research & Updates
    • Research Reports
    • Blog Posts
    • Notable Lessons
    • In the News
  • About Us
    • Grantmaking Process
    • How to Apply for Funding
    • Team
    • Contact Us
    • Stay Updated
  • We’re hiring!

Kainomyx — Antimalarial Drug (2019)

  • Portfolio Area: Human Health and Wellbeing
  • Focus Area: Scientific Research
  • Organization Name: Kainomyx
  • Amount: $1,999,999

  • Award Date: May 2020

Table of Contents


    Grant investigators: Chris Somerville and Heather Youngs

    This page was reviewed but not written by the grant investigators. Kainomyx staff also reviewed this page prior to publication.


    Open Philanthropy recommended an investment of $1,999,999 in Kainomyx to develop and produce a new antimalarial drug. If effective, the new drug would act by inhibiting cytoskeletal proteins in malarial parasites. Our science team believes that there is a need for new antimalarial drugs due to increasing artemisinin resistance to existing treatments.

    This falls within our work on scientific research, specifically within our interest in advancing human health and wellbeing.

    Related Items

    • Human Health and Wellbeing

      Yale University — Cardiovascular Research

      Open Philanthropy recommended a grant of $400,000 to Yale University to support research related to atherosclerosis, stroke, and cardiovascular function. This funding will go towards the purchase of...

      Read more
    • Human Health and Wellbeing

      University of Notre Dame — Biofilm-Resistant Catheters

      Open Philanthropy recommended a grant of $850,000 over three years to the University of Notre Dame to support work led by Professor Ana Flores-Mireles on developing a catheter design that...

      Read more
    • Human Health and Wellbeing

      Translational Health Science and Technology Institute — Henipavirus Antivirals

      Open Philanthropy recommended a grant of $1,020,475 over four years to the Translational Health Science and Technology Institute (THSTI). The THSTI is a government institute in the Department...

      Read more
    Back to Grants Database
    Open Philanthropy
    Open Philanthropy
    • Careers
    • Press Kit
    • Governance
    • Privacy Policy
    • Stay Updated
    Mailing Address
    Open Philanthropy
    182 Howard Street #225
    San Francisco, CA 94105
    Email
    [email protected]
    Media Inquiries
    [email protected]
    Anonymous Feedback
    Feedback Form

    © Open Philanthropy 2022 Except where otherwise noted, this work is licensed under a Creative Commons Attribution-Noncommercial 4.0 International License. If you'd like to translate this content into another language, please get in touch!